ライフサイエンスコーパス: dose reduction

1 ients (93%) achieved TCs of 3-7 mug/mL after dose reduction.

2 an 85% had worse survival than those without dose reduction.

3 and functional testing, as well as radiation dose reduction.

4 mong obese women was no longer apparent with dose reduction.

5 and quality of life may improve with opioid dose reduction.

6 ged with bosutinib interruption and 32% with dose reduction.

7 study inception and all achieved successful dose reduction.

8 h selumetinib, with 37% requiring at least 1 dose reduction.

9 l can be managed successfully with temporary dose reduction.

10 tube current, and AIDR3D with corresponding dose reduction.

11 treatment prematurely and the third required dose reduction.

12 anemia (39%) and was typically manageable by dose reduction.

13 diopharmaceutical doses, radiation risk, and dose reduction.

14 ore rapid image acquisition and/or radiation dose reduction.

15 atients (hemoglobin [Hb] <10 g/dL) after RBV dose reduction.

16 molytic anemia and decrease the need for RBV dose reduction.

17 he course of therapy and on the need for RBV dose reduction.

18 was 50% at 320 mg but improved to 25% after dose reduction.

19 %] patients), which generally resolved after dose reduction.

20 s could continue cetuximab treatment without dose reduction.

21 c reference level is recommended for further dose reduction.

22 b-paclitaxel, with more frequent and earlier dose reductions.

23 ts, and 21% of patients required carfilzomib dose reductions.

24 h standard doses of topotecan, necessitating dose reductions.

25 orafenib dose interruptions and 25 sorafenib dose reductions.

26 urred because of excessive toxicity, despite dose reductions.

27 time to simulate the corresponding relative dose reductions.

28 This level of dose reduction (1/40th of a full dose) is unprecedented

29 13,392 patients with no renal indication for dose reduction, 13.3% were potentially underdosed.

30 mGy for the 120-kVp protocol, yielding a 27% dose reduction (25% and 75% percentiles: 23% and 37%, re

31 (72% v 55%; P = .0038), longer time to first dose reduction (3.7 v 1.5 months), and lower proportion

32 te investigators as follows: EPO without RBV dose reduction, 38%; RBV dose reduction without EPO, 8%;

33 dose reduction without EPO, 8%; EPO with RBV dose reduction, 40%; and neither RBV dose reduction nor

34 e 1,473 patients with a renal indication for dose reduction, 43.0% were potentially overdosed, which

35 Eleven patients (50%) required dose reduction, 7 because of rash.

36 Furthermore, PET/MR offered significant dose reduction (73%) compared with PET/CT.

37 cm +/- 39 for all reduced-dose CTs (average dose reduction, 88.2%).

38 Toxicity leads to dose reduction, addition of colony-stimulating factors o

39 discontinue LTOT and patient outcomes after dose reduction among adults prescribed LTOT for chronic

40 (48.4%) of 31 patients required at least one dose reduction and 15 patients required temporary drug i

41 In conclusion, substantial dose reduction and daily administration of low doses of

42 Thus, CIPN is one of most common causes of dose reduction and discontinuation of what is otherwise

43 eprevir plus tacrolimus requires significant dose reduction and prolongation of the dosing interval f

44 of a hybrid CZT SPECT/64-slice CT system for dose reduction and to determine the maximal reduction po

45 comes, anemia, and their management with RBV dose reduction and/or erythropoiesis-stimulating agents

46 nemia (hemoglobin [Hb]<10 g/dL) included RBV dose reduction and/or erythropoietin (EPO) use.

47 icity with axitinib was generally managed by dose reduction and/or growth factor support.

48 he majority are mild and can be managed with dose reduction and/or temporary suspension of medication

49 with 7.7% of patients requiring carfilzomib dose reductions and 19.2% discontinuing CRd due to adver

50 tis incidence and severity, and the need for dose reductions and interruptions of everolimus.

51 ibavirin-induced hemolytic anemia can prompt dose reductions and lower sustained virologic response (

52 Toxicities were manageable with appropriate dose reductions and supportive care.

53 er versus shorter periods of prophylaxis and dose reductions and their impact on prevention of late-o

54 eptional responses can be achieved even with dose reductions and treatment breaks.

55 and diarrhea increased significantly in the dose-reduction and switch groups.

56 However, patients under agalsidase-beta dose-reduction and switch or a direct switch to agalsida

57 cial focus on renal outcome after 2 years of dose-reduction and/or switch to agalsidase-alpha.

58 ty-four (24.8%) of treated patients required dose reduction, and 5 (3.8%) of these patients subsequen

59 linary pain programs, buprenorphine-assisted dose reduction, and behavioral interventions, were found

60 des dose manipulations such as split dosing, dose reduction, and discontinuation.

61 erall, 40 (43%) of 92 patients had lapatinib dose reductions, and 27 (29%) of 92 patients had grade 3

62 e 3 or 4 treatment-related toxic effects, no dose reductions, and no more than two antihypertensive d

63 v four) and significantly more dose delays, dose reductions, and treatment discontinuations occurred

64 s leading to death, drug discontinuation, or dose reduction; and select AEs.

65 Simulated radiation dose reduction applied to clinical CT angiography for fa

66 no dose reduction, normal-weight women with dose reduction (ARDI < 85%) experienced worse survival (

67 ring for hematologic toxicity (grade B) with dose reduction as needed.

68 with reduced tube current to yield the same dose reduction as one bismuth shield; (e) with two layer

69 and were managed with dose interruption and dose reduction; asymptomatic and reversible reduction in

70 Radiation dose reduction at pediatric CT was achieved when 40% ASI

71 Patients who met clinical criteria for dose reduction at randomisation (n=5356) had higher rate

72 or higher incidence of adverse event-related dose reductions at higher trough concentrations.

73 Dose reduction averaged 50% (P < .001).

74 Dose reductions because of adverse events were more freq

75 Fewer dose reductions because of toxicity were required in the

76 ll-tolerated at 230 mg/m(2)/d, with a modest dose reduction being required when combining vorinostat

77 Dose reduction beyond this point resulted in overestimat

78 hat show considerable promise for additional dose reduction but are several years or more from commer

79 Many studies reported dose reduction, but rates of opioid discontinuation rang

80 With a radiation dose reduction by 2.36 mGy compared to standard of care

81 tal disease grading scale and corticosteroid dose reduction by at least 50%.

82 atient and to validate its use for potential dose reduction by using different image reconstruction a

83 ials aimed at estimating potential radiation dose reduction by using iterative reconstructions.

84 Conclusion A CT protocol with over 85% dose reduction can be used in patients with moderate to

85 Furthermore, the d' showed that the dose-reduction capabilities differed between clinical im

86 agnosis with the potential for a substantial dose reduction compared with PET/CT.

87 nterography with AIDR 3D allowed substantial dose reduction compared with that used with FBP CT enter

88 reconstruction may allow up to 59% radiation dose reduction compared with the dose with ASIR adaptive

89 erozygous for both, 100% required >/= 50% MP dose reduction, compared with only 7.7% of others.

90 carriers who were identified and received a dose reduction, compared with variant carriers who did n

91 % CI, 1.62-2.20) compared with those with no dose-reduction criteria (n = 13356).

92 Of the patients with 1 or no dose-reduction criteria assigned to receive the 5 mg twi

93 aban vs warfarin and the presence of 1 or no dose-reduction criteria were assessed.

94 s 5 mg twice daily; patients with at least 2 dose-reduction criteria-80 years or older, weight 60 kg

95 arfarin on major bleeding in patients with 1 dose-reduction criterion (HR, 0.68; 95% CI, 0.53-0.87) a

96 iterion (HR, 0.68; 95% CI, 0.53-0.87) and no dose-reduction criterion (HR, 0.72; 95% CI, 0.60-0.86) w

97 iterion (HR, 0.94; 95% CI, 0.66-1.32) and no dose-reduction criterion (HR, 0.77; 95% CI, 0.62-0.97) w

98 roke or systemic embolism in patients with 1 dose-reduction criterion (HR, 0.94; 95% CI, 0.66-1.32) a

99 Similar patterns were seen for each dose-reduction criterion and across the spectrum of age,

100 Little is known about patients with 1 dose-reduction criterion who received the 5 mg twice dai

101 us, and appropriate for patients with only 1 dose-reduction criterion.

102 ily dose of apixaban or warfarin, 3966 had 1 dose-reduction criterion; these patients had higher rate

103 ize should not be a major factor influencing dose reduction decisions in women with ovarian cancer.

104 Dose reduction decreased mean exposure by 29% (from 48.5

105 patients did not need dose adaptations, but dose reductions did not lead to an inferior survival.

106 Dose reduction/discontinuation of antipsychotics during

107 Short-term outcome studies of antipsychotic dose-reduction/discontinuation strategies in patients wi

108 asthma undergoing an inhaled corticosteroid dose reduction do not support the use of vitamin D suppl

109 These methods include dose reduction, dose intensification and new agents with

110 (8%) patients experiencing grade 3/4 events; dose reduction due to diarrhea occurred in 6% of affecte

111 Rates of discontinuation and dose reductions due to AEs were 17% and 10%, respectivel

112 19 (73%) patients required dose reductions due to drug-related adverse events.

113 ed on sorafenib treatment but required early dose reductions due to palmar plantar erythrodysesthesia

114 o dose-limiting toxicities and no individual dose reductions due to renal or hematologic toxicity wer

115 Two patients withdrew and 5 required IL-2 dose reductions due to side effects.

116 Dose reductions due to toxicity occurred in 52% of patie

117 Eight patients had dose reductions during therapy, and 7 patients discontin

118 s of hepatic dysfunction require appropriate dose reduction even though vorinostat pharmacokinetics a

119 on in mice at single nontoxic oral dose by a dose-reduction factor of 1.28.

120 e basis of patient size, while the pediatric dose reduction factors of this study allow calculation o

121 Pediatric dose reduction factors were calculated on the basis of S

122 The fractions of adult doses (pediatric dose reduction factors) used within the consortium for p

123 The average relative dose reduction for abdominopelvic CT was 29% (4.8/6.8 mG

124 d erythropoietin, blood transfusions, or RBV dose reduction for anemia.

125 0% ASIR implementation, the average relative dose reduction for chest CT was 39% (2.7/4.4 mGy), with

126 the radiologic imaging dose range, rendering dose reduction for children unjustifiable and counterpro

127 The relatively modest effect may reflect 50% dose reduction for each allergen in the mixture.

128 icities were observed; two patients required dose reduction for grade 3 fatigue and rash.

129 >/= 4 toxicity, but three patients required dose reduction for grade 3 rash.

130 In this procedure, dose reduction for particular organs ranged between 49-8

131 such as ASIR, enables substantial radiation dose reduction for pediatric CT when compared with FBP a

132 Moreover, we estimated the potential for dose reduction for PET/MR compared with PET/CT consideri

133 standard dose of melphalan 200 mg/m(2), with dose reduction for severe kidney dysfunction.

134 s of intravenous regimens with proportionate dose reductions for toxicity.

135 A radiation dose reduction from 70 to 50 Gy (RBE) did not seem to in

136 f the 87 patients (94%), with the percentage dose reduction greater for CT angiography than for chest

137 about 3 ml/min per 1.73 m(2) (P=0.01) in the dose-reduction group, and the median albumin-to-creatini

138 8), receive a reduced dose of 0.3-0.5 mg/kg (dose-reduction group, n=29), or switch to 0.2 mg/kg agal

139 Dose reductions had to be performed in 3 of 13 patients

140 eing a safety concern, substantial ribavirin dose reductions have to be considered in these patients,

141 s well as a lower rate of anemia-related RBV dose reduction (hazard ratio, 0.52; P = .0037).

142 The mean radiation dose reductions (ie, radiation protection) provided by X

143 Despite a 60% dose reduction, images reconstructed with SAFIRE allowed

144 d to CT protocol modifications for radiation dose reduction, improved diagnostic performance for dete

145 technology resulted in incremental radiation dose reduction in a statewide coronary computed tomograp

146 iscontinuation (period 2), and after the RAL dose reduction in arm 2 (period 3).

147 Each regimen incorporated a 50% dose reduction in patients with clinical features known

148 se swallowed fluticasone propionate (FP) and dose reduction in patients with eosinophilic esophagitis

149 nduced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepatitis C v

150 Lastly, radiation dose reduction in pediatric nuclear medicine is explicat

151 More dose reduction in the isocentric region was observed in

152 and other adverse effects, and they advised dose reduction in women and in older adults.

153 Anemia led to dose reductions in 13% of controls and 21% of boceprevir

154 AEs resulted in dose reductions in 17.2% of patients and drug discontinu

155 prior trastuzumab treatment, which prompted dose reductions in 29% and 4% of patients, respectively,

156 ppetite, nausea, and fatigue and resulted in dose reductions in 79% and holds in 65% of patients.

157 Adverse events led to dose reductions in six (14%) patients and treatment disc

158 ffect at concentration of 1.3 muM, 11.7-fold dose reduction index and no toxicity toward host cells.

159 openia and anemia, which were managed with a dose reduction, interruption of treatment, or transfusio

160 Accordingly, cytotoxic chemotherapy dose reduction is common in patients with elevated BMI.

161 This estimated dose reduction is somewhat smaller than that suggested b

162 ed to a linear, 2-compartment model in which dose reduction led to incomplete saturation of CD52 bind

163 e-beta dose had a stable disease course, but dose reduction led to worsening of renal function and sy

164 At moderate levels of dose reduction, lower-dose FBP images without ANLM or SA

165 e counts during peg-IFN/RBV therapy; peg-IFN dose reductions may be a consideration in patients with

166 e reduction or discontinuation, and this MMF dose reduction (MDR) can lead to rejection and possibly

167 brain region was slightly increased for all dose reduction methods.

168 feasible because of a high rate of lapatinib dose reduction, mostly caused by unacceptable grade 3 di

169 death compared with those who did not have a dose reduction (n=15 749).

170 ith RBV dose reduction, 40%; and neither RBV dose reduction nor EPO, 14%.

171 ompared with women with normal weight and no dose reduction, normal-weight women with dose reduction

172 The ease of administration coupled with the dose reduction observed in this study points to the Nano

173 Ease of administration coupled with dose reduction observed in this study suggests the Nanop

174 RBV dose reduction occurred in 25% without any treatment dis

175 Variant allele carriers received an initial dose reduction of >/= 50% followed by dose titration bas

176 Compared with FBP, ASIR enabled dose reduction of 46.4% (3.7 vs 6.9 mGy) for chest CT an

177 erozygous for the rs12777823 A allele need a dose reduction of 6.92 mg/week and those homozygous 9.34

178 MBIR allowed a dose reduction of 84% versus standard-dose ASIR 50% (mea

179 A reduced-dose protocol with MBIR allowed a dose reduction of 84% without increasing noise and witho

180 67%) in the study cohort achieved at least 1 dose reduction of any anti-diabetic medication.

181 e beta1 antibody, OS2966, allowing a 20-fold dose reduction of bevacizumab per cycle in this model.

182 The relationship between the dose reduction of BS/SC and some geometric parameters in

183 ad reactivation, required discontinuation or dose reduction of cancer treatment.

184 A dose reduction of lenalidomide 5 mg per day was required

185 Dose reduction of non-vitamin K antagonist oral anticoag

186 nsferase, the IL28B polymorphism rs12979860, dose reduction of peginterferon, and other covariates, o

187 , revealing a synergistic effect of combined dose reduction of these proteins.

188 Discontinuation or dose reduction of voriconazole resulted in improvement o

189 he use of an AP projection allowed for total dose reductions of 16%, 15%, and 12% for lungs, breast,

190 For radiation dose reductions of 25% or more, the ability to resolve t

191 Recommended colchicine dose reductions of 33-66% for the treatment of acute gou

192 Overall dose reductions of 48% and 61% were obtained for the 80-

193 GL/HDL ratio </= 3 to determine success with dose reductions of anti-diabetic medications showed a se

194 ive screening tool to determine success with dose reductions of anti-diabetic medications.

195 the two TLR agonists allows for significant dose reductions of each component to achieve a level of

196 another in vivo microCT platform resulted in dose reductions of over 9x (89%).

197 lymphoma (HL) is unclear, and the impact of dose reductions of these drugs on outcome and tolerabili

198 , the PDM patients received 2 fewer sedative doses (reduction of 38%) and had a reduction of 36% in s

199 rting after de-escalation (drug cessation or dose reduction) of anti-TNF agents and/or immunomodulato

200 dies (18 on de-escalation [drug cessation or dose reduction] of immunomodulator monotherapy, 8 on imm

201 eigh benefits, but evidence on the effect of dose reduction on patient outcomes has not been systemat

202 51) or placebo (n=5) to assess the effect of dose reduction on safety and immunogenicity.

203 research published in English that addressed dose reduction or discontinuation of LTOT for chronic pa

204 the only available treatment options involve dose reduction or discontinuation of therapy, which have

205 nevertheless, important because they prompt dose reduction or discontinuation of these life-saving m

206 late mofetil (MMF) side effects often prompt dose reduction or discontinuation, and this MMF dose red

207 , but they did not decrease the need for RBV dose reduction or increase the rate of SVR.

208 Dose reduction or interruption of vemurafenib is not req

209 Rates of dose reduction or suspension attributable to AEs were al

210 nd-organ damage and clinical symptoms during dose reduction or switch to agalsidase-alfa.

211 upper limit of normal, which resolved after dose reduction or temporary interruption of lomitapide.

212 %, and the estimated cumulative incidence of dose reduction or treatment discontinuation because of t

213 , these primary reactions rarely necessitate dose reduction or treatment interruption.

214 ated neutropenia commonly included antiviral dose reduction or withdrawal (51%).

215 d risk of relapse was high during medication dose reduction or withdrawal.

216 ured: 46% of patients' first DLTs and 88% of dose reductions or discontinuations of treatment because

217 EC-MPS was associated with fewer dose reductions or discontinuations, which may have tran

218 including discontinuation of anticoagulants, dose reduction, or low-molecular-weight heparin replacem

219 om toxicity were evaluated, including delay, dose reduction, or termination of chemotherapy.

220 rvention previously demonstrated significant dose reduction over a period of one year.

221 Dose reduction owing to toxic effects occurred in 56% of

222 16 (43%) patients required dose reductions owing to adverse events, the most freque

223 in a 28% reduction in drug cost from before dose reduction (P < .001).

224 which translated into an estimated radiation dose reduction potential (+/-95% confidence interval) of

225 onally, each metric was used to estimate the dose reduction potential of IR algorithms while maintain

226 FBP and SAFIRE and to estimate the radiation dose reduction potential of SAFIRE.

227 ttenuating liver lesions and to estimate the dose reduction potential of the IR algorithm in question

228 Radiation dose reduction potential ranged from 56% to 60% and from

229 dose in patients with a renal indication for dose reduction (potential overdosing) and use of a reduc

230 Dose reduction potentials based on both reading sessions

231 Despite the lower anti-FXa activity, dose reduction preserved the efficacy of edoxaban compar

232 Radiation dose reduction provided by the TCs was analyzed in 117 d

233 uced-dose images (generated from tube A; 60% dose reduction) reconstructed with sinogram-affirmed ite

234 A 50% dose reduction remained effective in 73%-93% of patients

235 Radiation dose reduction resulted in significantly improved swallo

236 rior LCR for vendors 1 and 2 for FBP and 25% dose reductions resulted in inferior and equivalent perf

237 Relative to FBP and full dose, 25%-50% dose reductions resulted in inferior LCR for vendors 1 a

238 TPase deficiency was not associated with RBV-dose reduction, RVR, or SVR.

239 over the course of therapy, ribavirin (RBV) dose reduction, serum RBV level, and rapid virological r

240 t least low disease activity) is maintained, dose reduction should be attempted.

241 Dose reductions should be taken into account to minimize

242 safety outcomes with warfarin stratified by dose reduction status.

243 Dose reduction strategies are often used to avoid chemot

244 diation exposure, radiation risk estimation, dose reduction strategies, and regulatory options.

245 Dose-reduction strategies targeted to the highest quarti

246 hypothesis under controlled conditions, this dose-reduction study was performed using a standardized

247 -based eGFR revealed decreasing eGFRs in the dose-reduction-switch group and the switch group.

248 equent switch to 0.2 mg/kg agalsidase-alpha (dose-reduction-switch group, n=28), or to directly switc

249 canned under six conditions: (a) without any dose reduction techniques (reference scanning); (b) with

250 r opinion, modern CT imaging with the use of dose reduction techniques and iterative reconstructions

251 d tomography have caused various advances in dose reduction technologies.

252 n risk, particularly for young children, and dose reduction tends to result in reduced resolution.

253 of IR, which indicates less potential for IR dose reduction than previously thought.

254 ura Clarity system resulted in a significant dose reduction, thereby leading to a significant decreas

255 sidual disease and/or allow for chemotherapy dose reduction, thereby leading to improved event-free s

256 Dose reduction through adsorption to aluminium hydroxide

257 ing, tissue perfusion imaging, and radiation dose reduction through iterative reconstruction are expl

258 A single-level dose reduction to 150 mg was made in 15 patients, all on

259 ed to warfarin or HDER (60 mg daily or a 50% dose reduction to 30 mg daily for CrCl 30-50 mL/min, bod

260 In conclusion, alemtuzumab dose reduction to 30 mg is safe in the context of reduce

261 In contrast, dose reduction to 30 mg on day -1 was associated with eq

262 ts may allow study of mixed extracts without dose reduction to improve efficacy.

263 sfusions while on ruxolitinib or ruxolitinib dose reduction to less than 20 mg twice a day with at le

264 rent globally by about 30% provides the same dose reduction to the eye as bismuth shielding; however,

265 Dose reductions to 1.2 mg/kg were instituted as a result

266 ed treatment without adverse event requiring dose reduction (tolerability), and elevation of urate as

267 achieved when 40% ASIR was implemented as a dose reduction tool only; no net change to the magnitude

268 ycles of ABVD is associated with substantial dose reduction, treatment delay, toxicity, and treatment

269 related, and resolved spontaneously or after dose reduction, use of antinausea drugs, or both.

270 th CT would potentially allow (18)F-fluoride dose reduction using hybrid (18)F-fluoride PET/MR imagin

271 40 studies examining patient outcomes after dose reduction (very low overall quality of evidence), i

272 The strongest predictor of dose reduction was a high BMI.

273 Lenalidomide dose reduction was associated with worse overall surviva

274 Dose reduction was determined by comparing size-specific

275 Mycophenolate mofetil dose reduction was independently associated with a subst

276 Dose reduction was needed in 2 patients and 2 others com

277 Dose reduction was required for a neutrophil count <0.75

278 Of patients with skin toxic effects, dose reduction was required for symptom management in 9

279 Peg-IFN or RBV dose reduction was required in 23% and 43% of patients,

280 This radiation dose reduction was seen with sinus rhythm (1.5 versus 16

281 s were significantly lower when FBP with 50% dose reduction was used.

282 different, regardless of whether 50% or 75% dose reduction was used.

283 The adjusted risk of dose reductions was significantly higher in MMF-treated

284 djusted differences in comfort and radiation dose reductions were calculated by using a mixed logisti

285 re assessed over a 21-day cycle; thereafter, dose reductions were implemented as needed and patients

286 Dose reductions were more frequent with 5.5 mg dose.

287 Dose reductions were necessary in 13 (7%) patients.

288 Subsequently, because toxicity-related dose reductions were necessary in the 110 mg cohort, we

289 Dose reductions were permitted for treatment-related tox

290 2, and the events most frequently leading to dose reductions were rash and arthralgia or arthritis.

291 ns repeatedly required profound voriconazole dose reductions whenever high-dose meropenem was added.

292 Efforts towards further dose reduction which would permit replacing chest X-ray

293 ffective treatment for CIPN exists, short of dose-reduction which worsens cancer prognosis.

294 rs intensively try to find new solutions for dose reduction while maintaining a high diagnostic value

295 h FBP, ADMIRE allows a substantial radiation dose reduction while preserving low-contrast detectabili

296 Further potential for radiotracer dose reduction, while maintaining PET image quality (IQ)

297 ons, many strategies have been developed for dose reduction with CTA.

298 f oil-in-water adjuvants in Europe permitted dose- reduction, with vaccines containing as little as 3

299 ws: EPO without RBV dose reduction, 38%; RBV dose reduction without EPO, 8%; EPO with RBV dose reduct

300 disease may increase bleeding risk, whereas dose reductions without a firm indication may decrease t